• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma

    ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma

  2. ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results

    ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results

  3. Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles

    Research and Markets: Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles

  4. Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles

    Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles

  5. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.